Articles and therapies for treating depression, with up-to-date information and clinical approaches that help understand and address this condition from different perspectives. In addition to traditional psychological interventions, there are now innovative treatments such as ketamine therapy, along with emerging lines of research exploring the therapeutic potential of substances such as psilocybin, MDMA, or 5-MeO-DMT for resistant cases.
These resources provide insight into how each approach can alleviate symptoms, promote new emotional insights, or unlock persistent thought patterns associated with depression. In specialised centres and settings, therapies are always administered under professional supervision and following rigorous protocols to ensure safety, efficacy, and adequate support throughout the process.
New therapies and treatments for depression and other mental health disorders are constantly being researched and developed. One of the most promising avenues currently under investigation is psychotherapy with 5-MeO-DMT, a short-acting psychoactive substance.
Treatment-resistant depression affects up to one third of patients with major depressive disorder and is linked to severe impairment and suicide risk. Real-world clinical data show that ketamine offers rapid antidepressant effects, with meaningful symptom reduction in nearly half of treated patients and remission in around one third. Benefits often appear within hours or days and can be maintained over time with follow-up treatment. Evidence also indicates good tolerability, low risk of symptom worsening and effectiveness in both unipolar and bipolar depression.
Microdosing psychedelics involves taking sub-perceptual doses of substances such as psilocybin or LSD with the aim of improving mood, cognition and emotional wellbeing. This article reviews current scientific evidence on microdosing, including proposed neurobiological mechanisms, potential benefits for depression and anxiety, cognitive and motivational effects, safety considerations and the role of placebo. While observational studies suggest possible benefits, controlled trials show mixed results, highlighting important limitations and the need for further rigorous research before clear clinical recommendations can be made.
Psilocybin-assisted therapy is emerging as a promising approach for depression, particularly treatment-resistant cases where standard antidepressants show limited efficacy and burdensome side effects. Research suggests psilocybin can produce rapid and sustained reductions in depressive symptoms, partly by enhancing neuroplasticity and facilitating meaningful psychological experiences. When embedded in a structured therapeutic model with preparation, dosing, and integration sessions, psilocybin may foster emotional openness, cognitive flexibility, and long-term positive change, highlighting a potential paradigm shift in how depression is treated within modern clinical research frameworks.
Depression, or major depressive disorder, is a common and complex condition marked by persistent low mood, loss of interest, cognitive difficulties and physical symptoms. Diagnosis is usually based on manuals such as the DSM-V by the American Psychiatric Association and the ICD by the World Health Organization, yet many people suffer without fitting rigid criteria. The text explores symptoms, stigma, limits of diagnostic labels and the need for a more holistic, humane approach to mental health care.
Treatment-resistant depression occurs when major depressive disorder does not respond to at least two adequate treatments, leading to prolonged suffering and functional impairment. Many patients fail to achieve full remission, despite multiple medication trials, increasing the risk of chronicity and hospitalization. Recent clinical evidence shows ketamine can produce rapid and meaningful symptom reduction in this population, including decreases in suicidal ideation and anxiety. Ongoing and maintenance ketamine sessions may further improve outcomes, offering new hope for patients who have not benefited from conventional antidepressant therapies
Depression is a complex disorder affecting mood, cognition, and physical health, and is the leading cause of disability worldwide. Standard treatment combines antidepressant medication and psychotherapy, yet around one third of patients do not respond adequately. This has driven interest in alternatives such as ketamine, a dissociative anesthetic with rapid antidepressant effects. Clinical trials and meta-analyses show symptom improvement within hours and remission in some patients. Ketamine is generally well tolerated and most effective when combined with psychotherapeutic support and careful medical supervision.
The information on this website is intended for healthcare professionals authorized to prescribe or dispense medications who practice their profession in Spain. Therefore, specialized training is required to interpret it correctly. The mentioned product may have a different authorized data sheet in other countries. By clicking the “Accept” button, you confirm that you are a healthcare professional authorized to prescribe or dispense medications and that you wish to access the information on this website in that capacity.